LAV describes itself on its About Us page as follows: "LAV is a global biomedical venture capital firm with offices in Hong Kong, Shanghai, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, we spun off to become an independent investment management company in 2011." The same page states "Our team of over 50 distinguished professionals, experienced in science, medicine, investment, and operations, embraces a culture of integrity, teamwork, diligence, and scientific rigor" and "Our vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital, and to help build great companies that develop breakthrough products to treat diseases and improve human health." The homepage states the focus as biopharmaceuticals, human therapeutics, medical devices and diagnostics, and the firm's stated philosophy is to bet on people and products, to favour quality science and to think long term. The Chinese site writes the firm's name as 礼来亚洲基金 and its sectors as 生物医药、医疗技术、医疗器械和诊断.